ICU Medical, Inc. (ICUI) Earnings

Management highlights

### Overall Financial Performance - Total Q2 2026 adjusted gross margin was 41%, in line with management expectations. Higher logistics costs from elevated diesel prices were offset by lower average tariff rates compared to original guidance. - Adjusted SG&A was $112 million (20.4% of adjusted revenue), down 1 percentage point year-over-year and quarter-over-quarter, driven by IT systems integration efficiencies and favorable expense timing. Adjusted R&D was $22 million (4.0% of adjusted revenue). - Adjusted EBITDA was $110 million (20% margin), with 10% year-over-year growth; adjusted diluted EPS was $2.37, a 13% increase year-over-year. - Free cash flow was $62 million for the quarter, including $20 million in tariff refunds. The company repaid $50 million of debt in Q2, ending the quarter with $1.24 billion of debt and a 2.3x net leverage ratio, on track to hit the 2x leverage target by end-2026. ### Strategic Progress & Product Innovation - Management confirmed nine consecutive quarters of acceptable revenue growth in the company's differentiated core businesses, with continued investments in R&D and capital despite past economic headwinds. - Infusion systems: The LifeShield, Plum Duo, and Solo product families are well received in the market. Substantial progress has been made on additional FDA verification testing for the MedFusion 5000 syringe pump, with an amended submission expected to the FDA in 2026. The company is close to delivering its vision of a fully connected suite of infusion devices with a common software platform for enterprise customers, with a clear development plan underway to connect home care CAD environments to the same framework. - Joint Venture Update: The Otsuka ICU Medical JV (Ivy Solutions) announced a $500 million investment to build a new U.S. production facility for PVC-free IV solutions, with a groundbreaking ceremony scheduled for August 24. This partnership is viewed as a win-win that will expand available product offerings for U.S. customers alongside ICU Medical's existing pumps and consumables. ### Capital Allocation & Portfolio Strategy - The company has protected its share base, with meaningful equity dilution only from the Hospira and Smith's Medical acquisitions. Minimal external M&A is planned, as the company has sufficient organic innovation pipeline in-house. - For Vital Care, all product lines are now cash flow positive, so management will not pursue value-destructive transactions to chase small growth improvements, and will continue pursuing logical strategic options aligned with value creation. - The long-term goal is to reach 2x or lower net leverage, appropriate for a mid-single-digit growing manufacturing company, with the ultimate goal of transferring value from debt to equity holders.

Guidance

- Full-year 2026 adjusted EBITDA guidance was raised and narrowed from the prior range of $400 million to $430 million to a new range of $415 million to $435 million. - Full-year 2026 adjusted EPS guidance was raised and narrowed from the prior range of $7.75 to $8.45 to a new range of $8.60 to $9.00. - Full-year adjusted gross margin is now expected to be approximately 41.5%, up from prior forecasts, as lower tariffs and accelerated synergy capture more than offset higher oil price impacts. - Adjusted operating expenses are still expected to be approximately 25% of total revenue for the full year. - Full-year net interest expense is expected to be approximately $65 million, with an adjusted effective tax rate of 25% and diluted weighted average shares outstanding of 25.2 million. - The full-year earnings contribution from the 40% equity JV is still expected to be breakeven or a small net loss. - Guidance assumes a stable macroeconomic environment, with inflation, currency, and interest rates holding at current levels, current forecasted oil/diesel prices, and no changes to existing tariff policy. The company expects to exceed its original 2026 goals set at the start of the year, and remains on track to hit the $150 million full-year free cash flow target.

Segment performance

ICU Medical reported total Q2 2026 revenue of $548 million, with 6% organic growth and 1% reported growth (reported growth was impacted by deconsolidation of the Otsuka joint venture IV Solutions business). 1. Consumables: Reported growth of 6%, 5% organic growth, with record absolute sales. Growth was balanced across all four product families, and this segment is expected to deliver mid-single-digit growth for the full year 2026. It contributed roughly 50-55% of total core company revenue. 2. IV Systems: Reported growth of 13%, 12% organic growth, with a record quarter for pump sales. Dedicated sets followed the same growth trend as consumables, and capital sales were strong. This growth was partially offset by OEM revenue declines that will continue through the remainder of the year. It contributed roughly 30-35% of total core company revenue. Organic growth of at or above 6% is expected for Q3 2026. 3. Vital Care: Organic revenue decreased 4%, reported revenue decreased 32% almost entirely due to the deconsolidation of IV solutions. The segment saw sequential improvement in Q2, and is expected to stabilize for the balance of the year, with a slight full-year decline given weak Q1 2026 results. It contributed roughly 10-15% of total core company revenue.

Risks & headwinds

- Negative currency impacts: Unfavorable movements in the Costa Rican colon, Mexican peso, and Japanese yen have created a cumulative negative impact of approximately $60 million over the past four years, with these currencies at 20-year extremes against the U.S. dollar, given the company's large production footprint in Costa Rica and Mexico and significant commercial sales in Japan. - Ongoing tariff headwinds: The company still faces $30 million to $40 million in annual incremental tariff costs that weigh on earnings. - Macroeconomic and commodity volatility: Volatility in oil and diesel prices creates uncertainty for logistics and production costs, and broader macro volatility makes financial forecasting more challenging. - FDA approval timing uncertainty: While the company expects to resubmit the MedFusion 5000 to the FDA in 2026, regulatory review timelines are not guaranteed and could delay product launch. - The company faces ongoing restructuring, integration, and quality system remediation costs that impact near-term cash flow, though these costs are expected to decline in the second half of 2026.

Analyst Q&A

• Q: Q2 IV systems growth was very strong at 12% organic. Is this driven by an uptick in customer replacement cycles, or is strength from other sources? Do prices for your new Duo and Solo pumps hold in the market? /

  A: The strong growth reflected early completion of installations from competitive wins secured in prior quarters, not a broad acceleration of replacement cycles, which the company has not yet started in earnest. Management confirms pricing for the new pumps holds, as the differentiated value of the new devices supports current price levels, which are aligned with the value delivered to customers.

• Q: What is the approximate size of the Q2 OEM headwind to IV systems growth, and is the OEM wind down now complete? Have customer replacement conversations started for 2027? /

  A: The OEM wind down will create a 1 to 2 percentage point drag on IV systems segment growth for the full year, and the drag is mostly complete after Q2. Some limited upgrade activity is already occurring for existing customers, but the majority of the large-scale upgrade cycle will start in 2027. The company is not pushing customers to upgrade earlier than their natural replacement cycle, with timing varying based on the age of existing installed hardware.

• Q: You received a $20 million tariff refund this quarter. Will additional future refunds be coming? How has the recent inflation and oil price impact compared to your expectations? /

  A: The $20 million received represents the majority of the IEPA tariffs the company paid, but not all. Small additional refunds may be possible in the second half of 2026 or 2027, but any future amounts will be much smaller than the $20 million received to date. Oil price impacts in Q2 were largely in line with expectations set after the Q1 call, and the updated guidance incorporates current forecasts for oil prices for the full year.

• Q: Is the SG&A efficiency from IT systems integration sustainable going forward? /

  A: The IT integration efficiencies will deliver ongoing benefits, but most of the Q2 SG&A improvement came through this quarter, and Q2 also benefited from temporary favorable expense timing that will not repeat in future quarters. Management noted the current Q2 SG&A run rate is not the expected long-term run rate, as the company will continue to invest appropriately in R&D and growth initiatives.